2. Apoptosis NF-κB Metabolic Enzyme/Protease Immunology/Inflammation
  3. Ferroptosis Keap1-Nrf2 FOXO NO Synthase Quinone Reductase
  4. NPB-1575

NPB-1575 is a potent, orally active and brain-penetrant anti-inflammatory agent. NPB-1575 mitigates neuroinflammation and resists ferroptosis by activating the IRS2/Nrf2/NF-κB axis. NPB-1575 shows protective effect against cerebral ischemic injury and improve the neurological functional prognosis. NPB-1575 can be used for the study of ischemic stroke.

For research use only. We do not sell to patients.

NPB-1575 Chemical Structure

NPB-1575 Chemical Structure

CAS No. : 161984-54-9

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

NPB-1575 Related Antibodies

Top Publications Citing Use of Products

View All FOXO Isoform Specific Products:

View All Isoforms
FOXO1 FOXO3

View All NO Synthase Isoform Specific Products:

View All Isoforms
nNOS iNOS eNOS

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

NPB-1575 is a potent, orally active and brain-penetrant anti-inflammatory agent. NPB-1575 mitigates neuroinflammation and resists ferroptosis by activating the IRS2/Nrf2/NF-κB axis. NPB-1575 shows protective effect against cerebral ischemic injury and improve the neurological functional prognosis. NPB-1575 can be used for the study of ischemic stroke[1].

In Vitro

NPB-1575 (1-10 μM, 6 h) exhibits anti-inflammatory effects by activating Nrf2 and inhibiting FOXO1 via IRS2/Akt signaling in LPS-stimulated BV2 cells[1].
NPB-1575 (1-10 μM, 12 h) attenuates inflammatory response in primary microglia cells via upregulating IRS2[1].
NPB-1575 (10 μM, 12 h) inhibits ferroptosis in ischemic stroke via upregulating IRS2 In the primary neuron-microglia transwell cell model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

NPB-1575 Related Antibodies

Western Blot Analysis[1]

Cell Line: LPS (HY-D1056) (1 μg/mL)-stimulated BV2 microglial cells
Concentration: 1, 3, 10 μM
Incubation Time: Cultured for 6 h and then stimulated with LPS for 6 h
Result: Significantly reduced iNOS and Iba1 protein expression dose-dependently.
Significantly increased IRS2 and phosphorylation of AKT.
Increased the levels of Nrf2, HO-1 and NQO-1 concentration-dependently.
Markedly reduced the levels of total FOXO1 and nucleus FOXO1.
Be blocked by IRS2 knockout, FOXO1 overexpression, LY294002(HY-10108) and ML385 (HY-100523).
Reduced NO and TNF-α releases.

Western Blot Analysis[1]

Cell Line: Primary neuron-microglia transwell cell, following LPS stimulation
Concentration: 1, 3, 10 μM
Incubation Time: 12 h
Result: Reversed the ferroptosis of neurons.
Regulated the levels of TFR1, ACSL4, SLC7A11 and GPX4.
In Vivo

NPB-1575 (25 mg/kg, p.o., single dose after surgery) attenuates neuroinflammation during cerebral ischemia and resist ferroptosis through the IRS2 in pMCAO rats[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Permanent occlusion of middle cerebral artery (pMCAO) model established in Male Sprague-Dawley rats with a weight of 260–280 g[1]
Dosage: 25 mg/kg
Administration: Oral gavage (p.o.), 5 min to 4 h after surgery (pMCAO), and behavioral recovery (limb-placing test, rotarod) at 3, 7, and 28 days post-pMCAO.
Result: Reduced the cerebral infarction volume of rats at 3 and 7 days after pMCAO.
Showed significant improvement in behavioral recovery up to 28 days after pMCAO.
Significantly increased level of IRS2 and the protein expression in the brain tissue.
Significantly reduced the levels of CD68, iNOS and NF-κB.
Persistent suppression of microglial activation (Iba1) and pro-inflammatory cytokines (TNF-α, IL-6).
Promoted AKT phosphorylation, raised Nrf2, HO-1, and NQO-1 levels and reduced FOXO1 expression.
Improved TFR1, ACSL4 and SLC7A11 and GPX4 levels via IRS2 and the effects were reversed by IRS2 knockdown.
Molecular Weight

314.38

Formula

C19H22O4
CAS No.
SMILES

OC1=CC(O)=C(C/C=C(C)/C)C(CCC2=CC(O)=C(O)C=C2)=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

NPB-1575 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

NPB-1575161984-54-9NPB1575NPB 1575FerroptosisKeap1-Nrf2FOXONO SynthaseQuinone ReductaseForkhead box ONitric oxide synthasesNOSIschemic strokeNeuroinflammationMicrogliaIRS2pMCAOanti-inflammatoryInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
NPB-1575
Cat. No.:
HY-174807
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.